PD(L)-1 antibodies are now established as an integral part of systemic therapy for many solid tumors, including gynecological malignancies such as breast cancer (early TNBC or metastatic TNBC), advanced endometrial cancer, advanced ovarian cancer, or metastatic cervical cancer. This evidence concerns the gene CD274 and ovarian carcinoma.